Background: Obstetric and perinatal outcome is an index of health in society. Various markers are being searched so as to increase the well being of mother and fetus in pregnancy. Several Studies [12,13] have revealed an association between microalbuminuria and obstetric outcome. Microalbuminuria can be used as prognostic marker in evaluation of gestational hypertension, preterm labour, GDM, PPROM, IUGR. Objective: This study was done to evaluate whether microalbuminuria which was evaluated at late second trimester could serve as marker for adverse obstetric and neonatal outcome.
Materials and Methods:A Prospective case control study was carried out on 150 people. Urine tested for urine micro albumin and creatinine and ACR ratio was calculated. Among 150 pregnant women 27 were positive for microalbuminuria and were categorised as group A. Pregnant women without microalbuminuria were considered as group B (controls). Both group A and group B were compared for obstetric outcomes. Results: Significant association found between group A and gestational hypertension and preterm labour. Conclusion: Microalbuminuria can be used as an early prognostic marker to detect adverse obstetric and neonatal outcome. It can be done in the late second trimester (around 18-24 weeks). It is a cheap, easily available method. Presence of microalbuminuria could therefore be a warning sign for the development of gestational hypertension and preterm delivery [14] . Hence presence of microalbuminuria needs further follow up and attention and strict blood pressure monitoring along with glycemic control in order to prevent adverse obstetric outcome of pregnancy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.